Using Tumor Markers for Early Detection of Breast Cancer Recurrence
Author Information
Author(s): R Molina, J Jo, G Zanon, X Filella, B Farrus, M Munioz, ML Latre, J Pahisa, M Velasco, P Fernandez, J Estape, AM Ballestal
Primary Institution: Hospital Clinic, School of Medicine, Barcelona, Spain
Hypothesis
Can c-erbB-2, CEA, and CA 15.3 improve early diagnosis of breast cancer recurrence?
Conclusion
C-erbB-2 is a useful tool for early diagnosis of metastases, especially in patients with c-erbB-2 overexpression in tissue.
Supporting Evidence
- 28% of patients with recurrence had elevated c-erbB-2 levels before diagnosis.
- Using all three markers increased sensitivity in early diagnosis by 11.2%.
- Specificity of the tumor markers was 100% for all three markers in NED patients.
Takeaway
Doctors can use special blood tests to find out if breast cancer has come back early, which can help treat it better.
Methodology
The study involved serial serum determinations of c-erbB-2, CEA, and CA 15.3 in 200 breast cancer patients with no evidence of residual disease.
Limitations
The study primarily focused on patients with no evidence of residual disease, which may limit generalizability.
Participant Demographics
Patients with primary breast cancer, mean follow-up of 2.2 years.
Statistical Information
P-Value
0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website